Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.04.19	Ipsen Reports Strong Double-Digit Sales Growth in First Quarter 2019 and Confirms Full Year 2019 Financial Targets (Businesswire)
18.04.19	Ipsen Completes Acquisition of Clementia Pharmaceuticals (Businesswire)
27.03.19	Ipsen Publishes its 2018 Registration Document (Businesswire)
28.02.19	Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference (Businesswire)
25.02.19	Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion (Reuters)
25.02.19	Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio (Businesswire)
18.01.19	Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief (Businesswire)
17.01.19	Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019 (Businesswire)
11.01.19	Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019 (Businesswire)
05.12.18	Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma (Businesswire)
20.11.18	Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087) (Businesswire)
15.11.18	European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib (Businesswire)
25.10.18	Ipsen Delivers Strong Sales Growth of 20.2%1 for the Third Quarter of 2018 and Confirms Full Year Guidance (Businesswire)
12.10.18	Ipsen to present new data from its oncology portfolio at the 2018 European Society for Medical Oncology (ESMO) congress (Businesswire)
21.09.18	Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC) (Businesswire)
19.07.18	Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients (Businesswire)
04.07.18	Ipsen Announces CELESTIAL phase 3 Pivotal Trial Results in the New England Journal of Medicine (Businesswire)
04.07.18	Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research (Businesswire)
04.06.18	Ipsen initiates a share buyback program to cover its free share allocation and employee share plans (Businesswire)
30.05.18	Combined Shareholders’ Meeting of IPSEN S.A. Held on 30 May 2018 (Businesswire)
30.05.18	IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 30 May 2018 (14th Resolution) (Businesswire)
29.05.18	Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership (Businesswire)
29.05.18	Ipsen Announces Clinical Data to Be Presented at ASCO Demonstrating Its Commitment to Patients with Cancer (Businesswire)
22.05.18	Ipsen launches employee share ownership plan (Businesswire)
17.05.18	European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (Businesswire)
26.04.18	Ipsen Reports Strong First Quarter 2018 Sales Growth of 23.1% at Constant Exchange Rates (Businesswire)
28.03.18	Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) (Businesswire)
26.03.18	Ipsen Publishes Its 2017 Registration Document (Businesswire)
23.03.18	Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma (Businesswire)
13.03.18	Ipsen appoints Ivana Magovcevic-Liebisch Ph.D., J.D. and Régis Mulot to Executive Leadership Team (Businesswire)
06.03.18	Ipsen Announces 18 Posters to Be Presented at the 15th Annual ENETS Conference (Businesswire)
21.02.18	Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies (Businesswire)
07.02.18	Ipsen Announces Eight Oral Presentations from Its Neurosciences Portfolio at the 10th World Congress for Neurorehabilitation (WCNR) (Businesswire)
22.01.18	End-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
16.01.18	Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma (Businesswire)
15.01.18	Ipsen Announces 13 Posters and 1 Oral Presentation at the 2018 ASCO Gastrointestinal Symposium (Businesswire)
12.01.18	Ipsen Appoints Richard Paulson Executive Vice-President and Chief Executive Officer of Ipsen North America (Businesswire)
12.01.18	IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.01.18	Ipsen Announces It is No Longer Eligible for the PEA-PME Scheme (Businesswire)
08.12.17	IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.12.17	Ipsen Announces Its Corporate Agenda for 2018 (Businesswire)
29.11.17	Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity (Businesswire)
14.11.17	IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
26.10.17	Ipsen Delivers Strong Sales Growth of 22.6%1 for the Third Quarter of 2017 and Confirms Full Year Guidance (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	536.40	1.02 %	K V
Part Grp Hldg	1’255.50	0.36 %	K V
Roche Hldg G	252.30	0.36 %	K V
Novartis	92.18	0.27 %	K V
Alcon	77.78	0.21 %	K V
CieFinRichemont	121.60	-0.61 %	K V
ABB	49.21	-0.67 %	K V
UBS Group	27.51	-0.90 %	K V
Sika	226.10	-1.09 %	K V
Logitech Intl	70.48	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten